Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Increased pressure within the pulmonary circulation due to lung or heart disorder.
Biomarker and diagnostic research for pulmonary hypertension has been reported in the published literature.
252 clinical trials registered, 115 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 7 PHASE4, 17 PHASE3, 28 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07176260](https://clinicaltrials.gov/study/NCT07176260) |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 8:25 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension |
— |
University Hospital, Strasbourg, France |
RECRUITING |
[NCT06570473](https://clinicaltrials.gov/study/NCT06570473) | Feasibility Trial for a Right Ventricular Failure Platform Trial | PHASE2 | University of Alberta | RECRUITING |
[NCT06573723](https://clinicaltrials.gov/study/NCT06573723) | Institutional Registry of Rare Diseases | — | Hospital Italiano de Buenos Aires | RECRUITING |
[NCT06409624](https://clinicaltrials.gov/study/NCT06409624) | Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension | — | University of Giessen | RECRUITING |
[NCT05442671](https://clinicaltrials.gov/study/NCT05442671) | iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | NA | Children's Hospital of Philadelphia | RECRUITING |
500 publications have been identified in PubMed for pulmonary hypertension. Research spans Review / Meta-Analysis (39%), Case Report / Case Series (18%), and Other (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 193 | 39% |
Patient case studies | 89 | 18% |
Other research | 88 | 18% |
Disease patterns and progression | 47 | 9% |
Laboratory research | 37 | 7% |
Testing and diagnosis research | 21 | 4% |
Clinical study results | 20 | 4% |
New treatment approaches | 5 | 1% |
Böger R (2026). [PMID: 42466514](https://pubmed.ncbi.nlm.nih.gov/42466514/). *J Am Heart Assoc*. [Other]
Mombeini H (2026). [PMID: 42025887](https://pubmed.ncbi.nlm.nih.gov/42025887/). *J Am Soc Echocardiogr*. [Other]
Singh Y (2026). [PMID: 41749628](https://pubmed.ncbi.nlm.nih.gov/41749628/). *Children (Basel)*. [Review / Meta-Analysis]
Baltodano Dangla CR (2026). [PMID: 42293359](https://pubmed.ncbi.nlm.nih.gov/42293359/). *Int J Cardiol Congenit Heart Dis*. [Case Report / Case Series]
Qin X (2026). [PMID: 41798614](https://pubmed.ncbi.nlm.nih.gov/41798614/). *Front Cardiovasc Med*. [Diagnostic / Biomarker]
Tsubata H (2026). [PMID: 41407361](https://pubmed.ncbi.nlm.nih.gov/41407361/). *Circ J*. [Clinical Trial Publication]
Kumar RK (2026). [PMID: 42639853](https://pubmed.ncbi.nlm.nih.gov/42639853/). *J Paediatr Child Health*. [Review / Meta-Analysis]
Falls C (2026). [PMID: 42814056](https://pubmed.ncbi.nlm.nih.gov/42814056/). *JACC Case Rep*. [Other]
Wang R (2026). [PMID: 41788734](https://pubmed.ncbi.nlm.nih.gov/41788734/). *Front Med (Lausanne)*. [Clinical Trial Publication]
Ghani H (2026). [PMID: 42710915](https://pubmed.ncbi.nlm.nih.gov/42710915/). *Eur Respir J*. [Other]
AI-curated news mentioning pulmonary hypertension
Updated Sep 29, 2026
A nationwide multicenter study investigates the long-term exposure to PM2.5 and its association with adverse pregnancy events in women with pulmonary hypertension. The findings contribute to understanding environmental impacts on pregnancy outcomes in this vulnerable population.
A case report details the late presentation of Lutembacher syndrome in an elderly female, highlighting severe pulmonary hypertension and tricuspid regurgitation complications. This case underscores the need for awareness of Lutembacher syndrome in older patients.
A recent EUSTAR cohort study evaluates the effectiveness of oral anticoagulants in treating precapillary pulmonary hypertension linked to systemic sclerosis. The findings contribute to understanding treatment options for this rare condition.
Roivant reports positive results from the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study highlights the drug's potential in addressing significant unmet medical needs in this progressive condition.
David Ross continues to advocate for rare diseases, particularly pulmonary hypertension associated with interstitial lung disease (PH-ILD), two decades after losing his loved one. His advocacy highlights the ongoing need for compassion and dedication in supporting patients facing these challenges.